SK&F 106760

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 598088

CAS#: 126053-71-2

Description: SK&F 106760 is a glycoprotein IIb/IIIa antagonist.

Chemical Structure

img
SK&F 106760
CAS# 126053-71-2
Instruction

Theoretical Analysis

MedKoo Cat#: 598088
Name: SK&F 106760
CAS#: 126053-71-2
Chemical Formula: C23H39N9O8S2
Exact Mass: 633.24
Molecular Weight: 633.740
Elemental Analysis: C, 43.59; H, 6.20; N, 19.89; O, 20.20; S, 10.12

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: SK&F 106760; SK&F-106760; SK&F106760; SKF 106760; SKF-106760; SKF106760;

IUPAC/Chemical Name: 2-((4R,7S,13R,16R)-16-acetamido-4-carbamoyl-13-(3-guanidinopropyl)-3,3,14-trimethyl-6,9,12,15-tetraoxo-1,2-dithia-5,8,11,14-tetraazacycloheptadecan-7-yl)acetic acid

InChi Key: MWLMZCNGBAIZSG-SZOQZIPDSA-N

InChi Code: InChI=1S/C23H39N9O8S2/c1-11(33)29-13-10-41-42-23(2,3)17(18(24)37)31-19(38)12(8-16(35)36)30-15(34)9-28-20(39)14(32(4)21(13)40)6-5-7-27-22(25)26/h12-14,17H,5-10H2,1-4H3,(H2,24,37)(H,28,39)(H,29,33)(H,30,34)(H,31,38)(H,35,36)(H4,25,26,27)/t12-,13-,14+,17+/m0/s1

SMILES Code: O=C(N[C@@H](CC(O)=O)C(N[C@@H](C(C)(C)SSC[C@@H](C(N([C@@H]1CCCNC(N)=N)C)=O)NC(C)=O)C(N)=O)=O)CNC1=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 633.74 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Willette RN, Sauermelch CF, Rycyna R, Sarkar S, Feuerstein GZ, Nichols AJ, Ohlstein EH. Antithrombotic effects of a platelet fibrinogen receptor antagonist in a canine model of carotid artery thrombosis. Stroke. 1992 May;23(5):703-11. PubMed PMID: 1605806.

2: Nichols AJ, Vasko JA, Valocik RE, Kopaciewicz LJ, Storer BL, Ali FE, Romoff T, Calvo R, Samanen JM. The in vitro pharmacological profile of SK&F 106760, a novel GPIIB/IIIA antagonist. Thromb Res. 1994 Jul 15;75(2):143-56. PubMed PMID: 7974388.

3: Nichols AJ, Vasko JA, Koster PF, Valocik RE, Rhodes GR, Miller-Stein C, Boppana V, Samanen JM. The in vivo pharmacological profile of the novel glycoprotein IIb/IIIa antagonist, SK&F 106760. J Pharmacol Exp Ther. 1994 Aug;270(2):614-21. PubMed PMID: 8071853.

4: Constantinides PP, Scalart JP, Lancaster C, Marcello J, Marks G, Ellens H, Smith PL. Formulation and intestinal absorption enhancement evaluation of water-in-oil microemulsions incorporating medium-chain glycerides. Pharm Res. 1994 Oct;11(10):1385-90. PubMed PMID: 7855039.

5: Samanen J, Wilson G, Smith PL, Lee CP, Bondinell W, Ku T, Rhodes G, Nichols A. Chemical approaches to improve the oral bioavailability of peptidergic molecules. J Pharm Pharmacol. 1996 Feb;48(2):119-35. Review. PubMed PMID: 8935160.

6: Willette RN, Storer BL, Clark RK, Ohlstein EH. Human laminin produces human platelet aggregation in vitro. Life Sci. 1994;55(5):379-88. PubMed PMID: 8035652.

7: Horton MA, Dorey EL, Nesbitt SA, Samanen J, Ali FE, Stadel JM, Nichols A, Greig R, Helfrich MH. Modulation of vitronectin receptor-mediated osteoclast adhesion by Arg-Gly-Asp peptide analogs: a structure-function analysis. J Bone Miner Res. 1993 Feb;8(2):239-47. PubMed PMID: 7680185.

8: Ali FE, Bennett DB, Calvo RR, Elliott JD, Hwang SM, Ku TW, Lago MA, Nichols AJ, Romoff TT, Shah DH, et al. Conformationally constrained peptides and semipeptides derived from RGD as potent inhibitors of the platelet fibrinogen receptor and platelet aggregation. J Med Chem. 1994 Mar 18;37(6):769-80. PubMed PMID: 8145226.

9: Samanen J, Ali F, Romoff T, Calvo R, Sorenson E, Vasko J, Storer B, Berry D, Bennett D, Strohsacker M, et al. Development of a small RGD peptide fibrinogen receptor antagonist with potent antiaggregatory activity in vitro. J Med Chem. 1991 Oct;34(10):3114-25. PubMed PMID: 1920361.